vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and TELOS CORP (TLS). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $46.8M, roughly 1.7× TELOS CORP). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -34.9%, a 25.3% gap on every dollar of revenue. On growth, TELOS CORP posted the faster year-over-year revenue change (77.4% vs -16.8%). Over the past eight quarters, TELOS CORP's revenue compounded faster (25.7% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Telos Corporation is an information technology and cybersecurity company located in Ashburn, Virginia. Telos primarily serves government and enterprise clients, receiving a large number of its contracts from the United States Department of Defense. Customers are primarily military, intelligence and civilian agencies of the US government and NATO allies.

BIOX vs TLS — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.7× larger
BIOX
$77.6M
$46.8M
TLS
Growing faster (revenue YoY)
TLS
TLS
+94.2% gap
TLS
77.4%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
25.3% more per $
BIOX
-9.6%
-34.9%
TLS
Faster 2-yr revenue CAGR
TLS
TLS
Annualised
TLS
25.7%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
TLS
TLS
Revenue
$77.6M
$46.8M
Net Profit
$-7.4M
$-16.3M
Gross Margin
46.8%
35.0%
Operating Margin
9.3%
-39.6%
Net Margin
-9.6%
-34.9%
Revenue YoY
-16.8%
77.4%
Net Profit YoY
-20.2%
-74.8%
EPS (diluted)
$-0.12
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
TLS
TLS
Q4 25
$46.8M
Q3 25
$77.6M
$51.4M
Q2 25
$36.0M
Q1 25
$60.6M
$30.6M
Q4 24
$98.8M
$26.4M
Q3 24
$93.3M
$23.8M
Q2 24
$28.5M
Q1 24
$84.0M
$29.6M
Net Profit
BIOX
BIOX
TLS
TLS
Q4 25
$-16.3M
Q3 25
$-7.4M
$-2.1M
Q2 25
$-9.5M
Q1 25
$-1.6M
$-8.6M
Q4 24
$605.2K
$-9.3M
Q3 24
$-6.2M
$-28.1M
Q2 24
$-7.8M
Q1 24
$9.8M
$-7.4M
Gross Margin
BIOX
BIOX
TLS
TLS
Q4 25
35.0%
Q3 25
46.8%
39.9%
Q2 25
33.2%
Q1 25
39.4%
39.8%
Q4 24
42.0%
40.3%
Q3 24
40.2%
13.2%
Q2 24
34.1%
Q1 24
50.8%
37.0%
Operating Margin
BIOX
BIOX
TLS
TLS
Q4 25
-39.6%
Q3 25
9.3%
-4.8%
Q2 25
-27.5%
Q1 25
1.5%
-29.5%
Q4 24
14.5%
-37.6%
Q3 24
2.5%
-121.4%
Q2 24
-30.3%
Q1 24
15.7%
-28.5%
Net Margin
BIOX
BIOX
TLS
TLS
Q4 25
-34.9%
Q3 25
-9.6%
-4.1%
Q2 25
-26.5%
Q1 25
-2.6%
-28.1%
Q4 24
0.6%
-35.4%
Q3 24
-6.6%
-118.0%
Q2 24
-27.2%
Q1 24
11.6%
-24.9%
EPS (diluted)
BIOX
BIOX
TLS
TLS
Q4 25
$-0.22
Q3 25
$-0.12
$-0.03
Q2 25
$-0.13
Q1 25
$-0.02
$-0.12
Q4 24
$0.00
$-0.13
Q3 24
$-0.10
$-0.39
Q2 24
$-0.11
Q1 24
$0.14
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
TLS
TLS
Cash + ST InvestmentsLiquidity on hand
$15.5M
$53.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$96.0M
Total Assets
$734.9M
$139.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
TLS
TLS
Q4 25
$53.2M
Q3 25
$15.5M
$59.0M
Q2 25
$57.0M
Q1 25
$38.5M
$57.8M
Q4 24
$29.2M
$54.6M
Q3 24
$32.3M
$69.8M
Q2 24
$80.1M
Q1 24
$16.4M
$93.9M
Stockholders' Equity
BIOX
BIOX
TLS
TLS
Q4 25
$96.0M
Q3 25
$288.3M
$119.7M
Q2 25
$118.4M
Q1 25
$345.0M
$126.1M
Q4 24
$346.3M
$127.1M
Q3 24
$346.0M
$129.5M
Q2 24
$149.1M
Q1 24
$348.5M
$154.4M
Total Assets
BIOX
BIOX
TLS
TLS
Q4 25
$139.9M
Q3 25
$734.9M
$164.3M
Q2 25
$165.0M
Q1 25
$798.2M
$158.1M
Q4 24
$835.2M
$158.2M
Q3 24
$827.3M
$166.3M
Q2 24
$182.4M
Q1 24
$836.1M
$195.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
TLS
TLS
Operating Cash FlowLast quarter
$14.4M
$8.0M
Free Cash FlowOCF − Capex
$8.0M
FCF MarginFCF / Revenue
17.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$29.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
TLS
TLS
Q4 25
$8.0M
Q3 25
$14.4M
$9.1M
Q2 25
$7.0M
Q1 25
$23.3M
$6.1M
Q4 24
$-5.4M
$-10.5M
Q3 24
$5.2M
$-7.1M
Q2 24
$-8.0M
Q1 24
$-17.4M
$-350.0K
Free Cash Flow
BIOX
BIOX
TLS
TLS
Q4 25
$8.0M
Q3 25
$8.7M
Q2 25
$6.8M
Q1 25
$6.0M
Q4 24
$-12.4M
Q3 24
$-7.1M
Q2 24
$-8.2M
Q1 24
$-447.0K
FCF Margin
BIOX
BIOX
TLS
TLS
Q4 25
17.0%
Q3 25
16.9%
Q2 25
19.0%
Q1 25
19.5%
Q4 24
-47.0%
Q3 24
-30.0%
Q2 24
-28.9%
Q1 24
-1.5%
Capex Intensity
BIOX
BIOX
TLS
TLS
Q4 25
0.1%
Q3 25
0.9%
Q2 25
0.4%
Q1 25
0.4%
Q4 24
7.1%
Q3 24
0.2%
Q2 24
0.8%
Q1 24
0.3%
Cash Conversion
BIOX
BIOX
TLS
TLS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

TLS
TLS

Security Solutions Segment$44.8M96%
Secure Networks Segment$1.9M4%

Related Comparisons